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Human genetics has indicated a causal role for the protein a-synuclein in the pathogenesis of familial Parkin-
son’s disease (PD), and the aggregation of synuclein in essentially all patients with PD suggests a central role
for this protein in the sporadic disorder. Indeed, the accumulation of misfolded a-synuclein now defines
multiple forms of neural degeneration. Like many of the proteins that accumulate in other neurodegenerative
disorders, however, the normal function of synuclein remains poorly understood. In this article, we review
the role of synuclein at the nerve terminal and in membrane remodeling. We also consider the prion-like
propagation of misfolded synuclein as a mechanism for the spread of degeneration through the neuraxis.Introduction
a-synuclein was independently discovered on multiple occa-
sions, providing important but still incompletely understood
clues to its normal function as well as its role in disease. It was
originally identified using an antibody to purified cholinergic
vesicles of the Torpedo electric organ (Maroteaux and Scheller,
1991), providing the first evidence of a presynaptic role. In addi-
tion to localization at the synapse, the antibody detected expres-
sion at the nuclear envelope, accounting for the designation
‘‘synuclein’’ (Maroteaux et al., 1988). Subsequent work has
confirmed the presence of a-synuclein in the nucleus (Gonc¸alves
and Outeiro, 2013; McLean et al., 2000; Mori et al., 2002).
However, synuclein is a small protein (140 amino acid residues)
that falls below the molecular weight cut off of the nuclear pore
(40 kDa). Although the distribution of synuclein may be influ-
enced by interaction with nuclear or cytoplasmic proteins (Goers
et al., 2003; Kontopoulos et al., 2006; Specht et al., 2005),
untagged, endogenous synuclein would thus be expected to
enter the nucleus on the basis of simple diffusion. The discovery
of a-synuclein in turn led to the identification of closely related
b- and g- isoforms (Maroteaux and Scheller, 1991).
Synuclein was also identified through the biochemical charac-
terization of senile plaques in Alzheimer’s disease (AD). Although
not as abundant as the Ab peptide, a fragment from themiddle of
a-synuclein (61–95) now termed the non-Ab component (NAC)
accumulates at high levels in plaques (Ue´da et al., 1993). More
recent work has shown that synuclein indeed contributes to
the pathology of AD as well as of dementia with Lewy bodies
(DLB) (Goedert, 1999; Trojanowski et al., 1998). However, this
role appears to reflect cytoplasmic deposition rather than
accumulation in extracellular plaques. Nonetheless, subsequent
analysis of the NAC precursor (a-synuclein) helped to establish
its primarily presynaptic localization (Iwai et al., 1995).
Third, a-synuclein mRNA transcripts were found to change
specifically within regions of the zebra finch brain involved in
control of song. Relative to other brain regions where synuclein
remains at high levels through development and maturity,
specific regions implicated in bird song show large, sustained
reductions in synuclein expression during song acquisition
(George et al., 1995). The regulated expression of synuclein1044 Neuron 79, September 18, 2013 ª2013 Elsevier Inc.within cell populations that participate in bird song has thus
suggested a specific role for the protein in synaptic plasticity,
but this role remains poorly understood.
Fourth, synuclein was purified as an inhibitor of phospholipase
D2 (PLD2), identifying a specific biochemical function for the
protein through a presumably unbiased experimental approach.
PLD enzymes cleave the headgroup of phosphatidylcholine
(PC) to release choline and phosphatidic acid (PA) and have
been implicated in membrane trafficking, particularly regulated
exocytosis (Hughes et al., 2004; Humeau et al., 2001; Vitale
et al., 2001; Zeniou-Meyer et al., 2007). In contrast to the PLD1
isoform, which acts downstream of an ADP ribosylating factor
(ARF) GTPase (Caumont et al., 1998; Cockcroft et al., 2002;
Colley et al., 1997), PLD2 has constitutive activity. To understand
how PLD2 might be regulated, factors that inhibit its function
were purified, resulting in the isolation of a- and b-synuclein
(Jenco et al., 1998). Additional work demonstrated a requirement
for multiple domains in synuclein to inhibit PLD2 (Payton et al.,
2004), but the physical interaction has not been documented.
Originally, genetic studies in yeast supported a role for synuclein
in PLD inhibition (Outeiro and Lindquist, 2003), but subsequent
work has not borne this out (Rappley et al., 2009a). Although
the initial purification of synuclein as a PLD inhibitor suggested
a specific biochemical function of potentially profound signifi-
cance, the biological relevance of this finding has thus remained
uncertain.
Fifth, point mutations in a-synuclein were found to cause an
autosomal dominant form of Parkinson’s disease (PD) (Kru¨ger
et al., 1998; Polymeropoulos et al., 1997; Zarranz et al., 2004).
The clinical phenotype resembles idiopathic PD, with typical
tremor, rigidity, and bradykinesia, and the pathology shows
cytoplasmic Lewy body inclusions characteristic of PD (Golbe
et al., 1996), strongly suggesting relevance for the sporadic
disorder. Indeed, mutations in a-synuclein account for only a
tiny fraction of PD in the general population, but the Lewy
bodies and dystrophic neurites observed in idiopathic PD label
strongly for a-synuclein (Galvin et al., 1999; Spillantini et al.,
1997, 1998b). Immunostaining for a-synuclein subsequently
revealed abundant inclusions not previously detected using
standard histological methods (Jellinger, 2011). In fact, many
Figure 1. The N Terminus of Synuclein
Contains Seven 11 Residue Repeats that
Form a Helix on Membrane Binding
The consensus sequence of the repeats is shown
to the left and helical wheel to the right. The height
of the single letter amino acid code indicates the
probability of finding that particular residue in the
repeats of human a-synuclein. Blue indicates
basic, red acidic, purple polar uncharged, and
black nonpolar residues.
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bodies recognize a-synuclein (Giasson et al., 2000b), supporting
the impression that although other proteins may also accumu-
late in the inclusions of PD, a-synuclein predominates. Taken
together, the genetic evidence for a causative role and the
neuropathologic evidence for accumulation in essentially all
patients with PD indicate a central role for synuclein in the
idiopathic disorder.
The Structure of Synuclein
The N terminus of a-synuclein contains seven 11 residue repeats
that are predicted to form an amphipathic alpha-helix (Figure 1).
The repeats are very highly conserved, both across species and
among the three different isoforms. Themotif is also unique, with
no similar sequence identified outside the synuclein family. In
addition, this sequence has been detected only in vertebrates,
including the lamprey (Busch and Morgan, 2012). Remarkably,
all of the mutations associated with PD—A53T, A30P, and
E46K as well as the more recently described G51D and H50Q
(Appel-Cresswell et al., 2013; Kru¨ger et al., 1998; Lesage et al.,
2013; Polymeropoulos et al., 1997; Proukakis et al., 2013;
Zarranz et al., 2004)—cluster within this N-terminal domain. It
is also interesting to note that rodent synuclein normally contains
a threonine at position 53, which causes PD in humans. The A53T
mutation thus appears pathogenic specifically within the human
context. Model genetic organisms such as worms, flies, and
yeast do not contain identifiable homologs, indicating that the
synucleins are not required for synaptic transmission or mem-
brane trafficking more generally. On the other hand, the apolipo-
proteins and a set of plant proteins that accumulate during
desiccation and seed formation also contain amphipathic
a helices with 11 residue repeats (George et al., 1995).
Repeats of this size enable the polypeptide to make exactly
three turns of the helix and thus interact directly with the
surface of a membrane through multiple repeats. However, the
sequence of apolipoprotein and plant seed proteins bears little
if any obvious similarity to the synucleins.
Purified, recombinant synuclein behaves like a natively
unfolded protein in vitro (Bertoncini et al., 2005; Weinreb et al.,
1996) but, as predicted from the sequence, forms an a-helix onNeuron 79, Sepbinding to artificial membranes (Davidson
et al., 1998). Shown initially by circular
dichroism, the conformational change
associated with membrane binding re-
quires acidic phospholipid headgroups,
suggesting an interaction of the mem-
brane with lysines found on oppositesides of the helix (Figure 1). There is minimal specificity for a
particular acidic headgroup, with phosphatidylserine recognized
as well as phosphatidic acid and phosphatidylinositol (Zhu and
Fink, 2003). Nuclear magnetic resonance (NMR) studies of syn-
uclein on SDSmicelles also reveals an a-helix but bent, presum-
ably due to the small size of themicelle (Eliezer et al., 2001; Ulmer
et al., 2005). On membranes, which have a larger diameter than
micelles, the analysis of spin-labeled protein shows that
synuclein adopts the extended 11/3 helix predicted from the
sequence (Jao et al., 2004). Synuclein also lies along the surface
of the membrane, at least half-buried in the bilayer (Bussell et al.,
2005; Jao et al., 2008; Wietek et al., 2013).
Despite the original description as a natively unfolded protein,
recent work has suggested that a-synuclein may in fact remain
helical in solution, with important implications for its normal
function and its susceptibility to aggregation. The evidence for
intrinsic disorder has depended primarily on the analysis of
bacterially expressed recombinant protein, and a denaturation
step used by some groups in the purification has been sug-
gested to account for the unfolded state (Bartels et al., 2011;
Wang et al., 2011). Consistent with a lack of folding, synuclein
behaves like a much larger protein by size exclusion chromatog-
raphy, but multimerization is another possibility. To assess the
multimeric state of native synuclein, a recent study from the
Selkoe laboratory used a combination of crosslinking and ana-
lytical ultracentrifugation to determine the molecular weight of
mammalian synuclein isolated from red blood cells and cell
lines. In contrast to previous studies, this work found that
native a-synuclein behaves as a folded, helical tetramer (Bartels
et al., 2011). Electron microscopy (EM) reconstruction and NMR
of protein purified under nondenaturing conditions further sug-
gested a multimeric state that resists aggregation (Wang et al.,
2011). However, subsequent work using recombinant synuclein
has confirmed that even the nondenatured recombinant protein
is intrinsically disordered and loses its a-helical conformation
after dissociation from membranes (Fauvet et al., 2012). Loss
of helicity could thus reflect the dilution inherent in preparing
an extract, with the helical state maintained at higher concentra-
tions (Dettmer et al., 2013;Wang et al., 2011), but NMR studies in
E. coli have in fact suggested that macromolecular crowdingtember 18, 2013 ª2013 Elsevier Inc. 1045
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2006). It is also possible that synuclein folds to form a multimer
only in mammalian cells, but the analysis of native brain synu-
clein has recently confirmed its almost entirely monomeric state
(Burre´ et al., 2013). Recently, it has also been shown that
synuclein can assemble into an oligomer (possibly tetramer) on
nanoparticles (Varkey et al., 2013), but this phenomenon seems
to differ from the ability of a preformed tetramer to interact with
membranes (Wang et al., 2011). At this point, it remains possible
that a-synuclein adopts a helical tetrameric state in solution,
but the evidence is not definitive. The unavoidable dilution that
accompanies purification of native synuclein complicates the
analysis, but it is perhaps more important to acknowledge that
despite extensive biochemical studies in vitro, the conformation
of synuclein in cells remains poorly understood.
In contrast to the N-terminal membrane binding domain, the
C terminus of human a-synuclein is polar, with a higher pro-
portion of charged residues. This domain undergoes phosphor-
ylation at multiple sites (Oueslati et al., 2010; Sato et al., 2013),
suggesting a mechanism for regulation, but the function of the
C terminus remains unclear, and it is the least conserved domain
across species as well as among a-, b-, and g- isoforms. The
C terminus may affect membrane binding under particular
conditions (Shvadchak et al., 2011), but phosphorylation toward
the end of the N-terminal repeats, at Ser-87, more clearly affects
membrane binding in vitro than phosphorylation at the other,
more C-terminal sites (Paleologou et al., 2010). The observations
thus suggest a potential biological role for Ser-87 phosphoryla-
tion, although this again remains to be identified in the context
of the cell.
Membrane Interactions and the Presynaptic Location
of Synuclein
The presynaptic location of a-synuclein has been recognized
since its original identification as a protein associated with
synaptic vesicles (Maroteaux et al., 1988). In contrast to many
proteins involved in neurodegeneration that are distributed
throughout the neuron, however, a-synuclein localizes specif-
ically to the nerve terminal, with relatively little in the cell body,
dendrites, or extrasynaptic sites along the axon (George et al.,
1995; Iwai et al., 1995). Several nonneural tissues including red
blood cells also express a-synuclein (Barbour et al., 2008), but
the protein is relatively specific to the nervous system (Iwai
et al., 1995). In addition, a-synuclein is widely expressed by
many neuronal populations within both central and peripheral
nervous systems, suggesting a general role in neuronal function.
However, a-synuclein appears to be one of the last proteins
that localizes to developing synapses, arriving after integral
membrane proteins of the synaptic vesicle and the peripheral
membrane synapsin proteins (Withers et al., 1997). Consistent
with its restriction to the vertebrate lineage, its accumulation
at the synapse thus does not appear essential for synapse devel-
opment or function.
Similar to a-synuclein, the b- isoform also exhibits a presynap-
tic location (Jakes et al., 1994; Mori et al., 2002; Quilty et al.,
2003). Indeed, a- and b- isoforms colocalize at many but not
all presynaptic boutons. However, g-synuclein is expressed
by glia and only specific neuronal populations, in particular1046 Neuron 79, September 18, 2013 ª2013 Elsevier Inc.dopamine neurons (Brenz Verca et al., 2003; Galvin et al.,
2001). g-synuclein is also expressed by a variety of cancers
(breast, colon, pancreas) in which it apparently contributes to
tumor progression through a number of potential mechanisms
(Hua et al., 2009; Inaba et al., 2005; Ji et al., 1997; Pan et al.,
2002).
Despite the original association with synaptic vesicles, it has
been unclear how a-synuclein localizes to the nerve terminal.
In the absence of an obvious transmembrane domain or lipid
anchor, synuclein presumably relies on the N-terminal repeats
for membrane binding in cells, similar to the observations with
artificial membranes made in vitro. However, fractionation of
brain extracts reveals a very weak association with synaptic
vesicles, and the vast majority of synuclein behaves as a soluble
protein (Fortin et al., 2004; Kahle et al., 2000). These observa-
tions suggest that the association with native synaptic vesicles
is weak, or disrupted, by the procedures required for bio-
chemical fractionation: dilution alone could result in the loss of
synuclein from synaptic vesicles. To examine the mobility of
synuclein in intact cells, cultured hippocampal neurons were
therefore transfected with GFP-tagged synuclein and individual
presynaptic boutons subjected to photobleaching. The synaptic
fluorescence recovered quite rapidly (within seconds) after
photobleaching, indicating that the protein is highly mobile
(Fortin et al., 2004). More recently, this approach has been
extended in vivo, to cortical neurons of transgenic mice express-
ing a-synuclein-GFP (Unni et al., 2010). In this case, recovery
occurredmore slowly (over minutes) but this presumably reflects
the altered geometry in vivo, with adjacent synapses (and un-
bleached synuclein-GFP) simply further away from the bleached
boutons. However, synapseswith higher expression of synuclein
also showed less complete recovery, raising the possibility that
aggregation contributes. Not surprisingly, fluorescence recovery
after photobleaching in aC. elegansmodel of inclusion formation
by synuclein inmuscle has shown a substantial immobile fraction
(van Ham et al., 2008). The results in neurons with more physio-
logical levels of expression thus indicate that synuclein interacts
weakly with elements of the nerve terminal.
Despite its weak interaction with cellular membranes, synu-
clein nonetheless recovers more slowly after photobleaching
than GFP (Fortin et al., 2004), and the N-terminal membrane-
binding domain of synuclein seems likely to mediate the inter-
action. The A30P mutation associated with familial PD in fact
disrupts both the association of synuclein with brain membranes
and the presynaptic location of synuclein in cultured neurons and
accelerates the rate of recovery after photobleaching to that of
GFP (Fortin et al., 2004; Jensen et al., 1998). The A30P mutation
also impairs the interaction of purified, recombinant synuclein
with artificial membranes (Jo et al., 2002). Although less dramatic
in vitro than in cells, the effect of the A30P mutation strongly
supports a role for membrane binding by the N terminus in pre-
synaptic localization.
How then does synuclein localize specifically to presynaptic
boutons rather than other cell membranes? Acidic headgroups
are found on the cytoplasmic leaflet of many intracellular mem-
branes, but synuclein has a preference for membranes with
high curvature (Jensen et al., 2011; Middleton and Rhoades,
2010), and synaptic vesicles are among the smallest biological
Neuron
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from presynaptic boutons with stimulation (Fortin et al., 2005),
suggesting that it dissociates from the membrane upon delivery
to the relatively flat plasma membrane by synaptic vesicle
exocytosis.
What confers the specificity of synuclein for membranes
with high curvature? Interestingly, the hydrophobic face of the
N-terminal a-helix contains a series of threonines at position
3 in the repeat (Figure 1). Although this polar residue might be
expected to disrupt hydrophobic interactions with the mem-
brane, threonine is in fact less polar than serine, and the precise
positioning of this residue in repeats 2–5 and 7 is highly
conserved among all synuclein isoforms. It is therefore possible
that threonine at these positions weakens the interaction of
synuclein with membranes precisely so that it can acquire spec-
ificity for high curvature. To test this possibility, the threonines
were replaced by large, nonpolar residues (leucine and phenylal-
anine) and the recombinant mutant protein indeed loses its
specificity for both acidic membranes and small vesicles (Pranke
et al., 2011). When expressed in yeast, the mutant also localizes
to the plasma membrane rather than to intracellular vesicles,
consistent with stronger membrane interaction interfering with
the preference for high curvature.
In addition to acidic phospholipid headgroups and high
curvature, synuclein appears to have a preference for specific
membrane microdomains. Since the large proportion of soluble
synuclein makes it difficult to detect a membrane-bound frac-
tion by morphological techniques in most cells other than neu-
rons, digitonin was used to permeabilize selectively the plasma
membrane of HeLa cells expressing human a-synuclein,
releasing the unbound cytosolic protein (Fortin et al., 2004).
The remaining synuclein appeared punctate but failed to coloc-
alize with markers for many organelles. Rather, it colocalized
with components of lipid rafts, a membrane microdomain
with reduced fluidity that is enriched in cholesterol and satu-
rated acyl chains (Fortin et al., 2004). The PD-associated
A30P mutation abolished this localization, supporting the spec-
ificity of the interaction, and the biochemical analysis of deter-
gent-resistant membranes by flotation gradient confirmed the
localization to rafts. Importantly, the disruption of lipid rafts
also prevents the accumulation of synuclein in presynaptic
boutons (Fortin et al., 2004), supporting the relevance of this
interaction for neurons. In addition to the requirement for acidic
phospholipid, biochemical studies in vitro have indicated that
synuclein requires a combination of phospholipid with oleoyl
as well as polyunsaturated acyl chains (Kubo et al., 2005), sug-
gesting that it may specifically recognize the phase boundary
that arises between membranes that differ in fluidity. Remark-
ably, there was an apparent requirement for the acidic head-
group on the polyunsaturated acyl rather than oleoyl chain
(Kubo et al., 2005), raising the possibility of a distinct and pre-
viously unknown microdomain in neurons. Further, recent work
has found that synuclein can influence lipid packing within raft-
like domains containing cholesterol (Leftin et al., 2013), sug-
gesting that synuclein may not simply be recruited by these
structures but also contributes to their formation, very similar
to other peripheral membrane proteins such as caveolin (Parton
and del Pozo, 2013).It has also been suggested that synuclein might act as a fatty
acid binding protein (Sharon et al., 2001). Synuclein promotes
the uptake of polyunsaturated fatty acids into cells, and polyun-
saturated fatty acids promote the oligomerization of synuclein
(Assayag et al., 2007; Perrin et al., 2001; Sharon et al., 2003a,
2003b). Supporting a role for this activity in vivo, the analysis of
a-synuclein knockout mice has shown remarkable changes in
brain cardiolipin, including acyl chain composition (Ellis et al.,
2005). Fatty acid uptake and metabolism also appear affected
(Golovko et al., 2005, 2006, 2007), although with only modest
changes in other brain phospholipids (Barcelo´-Coblijn et al.,
2007; Rappley et al., 2009b). g-synuclein knockouts also show
only modest brain region-specific changes in both phospholipid
headgroup and acyl chain composition (Guschina et al., 2011).
Nonetheless, even small changes in acyl chain composition
may influence membrane fluidity and trafficking, and the expres-
sion of a-synuclein appears to promote clathrin-dependent
endocytosis (Ben Gedalya et al., 2009).
The Role of Synuclein in Neurotransmitter Release
The presynaptic location of synuclein and its interaction with
membranes have strongly suggested a role in transmitter
release. Several of the original publications indeed reported
that a-synuclein promotes release (Cabin et al., 2002; Murphy
et al., 2000), but others suggested an inhibitory role. Dopamine
release by a-synuclein knockout mice recovers faster from re-
petitive stimulation than in wild-type animals, and the knockouts
show amild reduction in striatal dopamine stores consistent with
increased release (Abeliovich et al., 2000). The analysis of dopa-
mine and norepinephrine release by knockout mice in vivo also
shows more rapid facilitation than in wild-type and reduced
depression after multiple bursts of stimulation (Yavich et al.,
2004, 2006). These effects on dopamine release in vivo are
among the most dramatic reported for a-synuclein knockout
mice and suggest a major disturbance in the mobilization of syn-
aptic vesicles. However, the findings at glutamate synapses are
much less striking (Abeliovich et al., 2000; Chandra et al., 2004).
To mimic the increase in expression that causes PD in families
with a duplication or triplication of the gene, a-synuclein has also
been overexpressed both in culture and in transgenic mice.
Although the overexpression of PD-associated or C-terminal
truncation mutants can produce a degenerative process in vivo
(Giasson et al., 2002; Gispert et al., 2003; Gomez-Isla et al.,
2003; Lee et al., 2002b; Shults et al., 2005; Yazawa et al.,
2005), nonviral overexpression of the wild-type protein usually
produces little toxicity (Matsuoka et al., 2001). Transgenic mice
overexpressing the wild-type human protein do show a number
of behavioral abnormalities relating to olfaction, gastrointestinal
motility, and motor activity (Fleming et al., 2008; Kuo et al., 2010;
Noorian et al., 2012; Wang et al., 2008), suggesting that these
animals may reproduce the prodromal phase of PD, but there
is little if any detectable degeneration.
To understand how overexpression of synuclein might affect
behavior and cause PD, the analysis was extended to synaptic
physiology and a direct analysis of the release mechanism. First
studied in chromaffin cells, overexpression of the wild-type
human protein was found to inhibit the exocytosis of dense
core vesicles as measured by direct amperometric recordingsNeuron 79, September 18, 2013 ª2013 Elsevier Inc. 1047
Figure 2. Overexpression of a-Synuclein in Rat Hippocampal
Neurons Inhibits Synaptic Vesicle Exocytosis
Embryonic rat hippocampal neurons were transfected with VGLUT1-pHluorin
and either wild-type human a-synuclein or empty vector. After growth in
culture for 2 weeks, the cells were stimulated at 10 Hz for 60 s and the
response of VGLUT1-pHluorin monitored. Quenched at the low pH of synaptic
vesicles, the pHluorin (a modified form of GFP shifted in its pH sensitivity)
becomes more fluorescent when exposed to the external pH during exocy-
tosis. The reacidification that follows endocytosis results in the quenching of
fluorescence. NH4Cl is used to alkalinize all of the intracellular VGLUT1-
pHluorin pool and demonstrates that synuclein overexpression does not
reduce expression of the reporter. Overexpression of synuclein impairs the
exocytosis of synaptic vesicles but has no apparent effect on endocytosis after
normalization to peak stimulated fluorescence. (Reproduced from Nemani
et al., 2010.)
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not involve a change in calcium sensitivity, quantal size, or the ki-
netics of individual quantal events but rather a reduction in the
number of events. The PC12 cell granules also appear to accu-
mulate at the plasma membrane, suggesting a specific defect
at or close to the fusion event, and the A30Pmutant had an effect
surprisingly similar to wild-type human synuclein considering its
defect in membrane interactions (Larsen et al., 2006).
In cultured neurons, overexpression of the wild-type human
protein at levels that do not produce deposits or obvious toxicity
causes an inhibition of synaptic vesicle exocytosis as measured
by optical imaging of both hippocampal and midbrain dopamine
neurons (Nemani et al., 2010) (Figure 2). Modest overexpression
in transgenic mice produced a similar defect in neurotransmis-
sion measured by postsynaptic recording at hippocampal CA1
synapses (Nemani et al., 2010). It is also important to note that
there was no change in quantal size. Several reports have shown
that multimeric synuclein can form pores in artificial membranes
in vitro (Rochet et al., 2004; Tsigelny et al., 2007; Volles et al.,1048 Neuron 79, September 18, 2013 ª2013 Elsevier Inc.2001). This should dissipate the H+ electrochemical gradient
that drives neurotransmitter uptake into vesicles; however, the
lack of change in quantal size argues further against pore forma-
tion by multimers, at least in these cells. Although previous work
on the role of synuclein in transmitter release had identifiedmajor
defects only in monoamine neurons, these findings indicated
that the disturbance with overexpression is more general.
Imaging further demonstrated a specific defect in exocytosis,
with no change in the endocytosis of synaptic vesicle membrane
despite the effects on clathrin-dependent endocytosis observed
in other cells (Ben Gedalya et al., 2009). In contrast to LDCV
release by chromaffin cells (Larsen et al., 2006), the A30P muta-
tion abolishes the effect of synuclein overexpression on synaptic
vesicle exocytosis (Nemani et al., 2010). Presumably, the
specific accumulation of synuclein at release sites (disrupted
by the A30P mutation) is more important for neurons, with
many long processes, than for small, compact chromaffin cells.
However, electron microscopy in the transgenic mice overex-
pressing synuclein also showed a dispersion of synaptic vesicles
away from the active zone and into the axon (Nemani et al.,
2010), and it is more difficult to reconcile this observation with
the accumulation of secretory granules at the plasmamembrane
in chromaffin cells that overexpress synuclein (Larsen et al.,
2006). Recent ultrastructural analysis of a different transgenic
mouse line has shown enlargement of boutons and convoluted
internal membranes connected to the cell surface (Boassa
et al., 2013).
The precise nature of the defect in synaptic vesicle exocytosis
remains unclear. Interestingly, the transgenic mice show a
reduction in synapsins and complexin, consistent with a change
in exocytosis. Subsequent work has also shown a defect in
transmitter release with overexpression of synuclein in hippo-
campal cultures. However, this study described ‘‘vacant
synapses’’ that were devoid of synaptic vesicle proteins and
contained abnormal membranes that were not observed in other
systems, suggestive of toxicity (Boassa et al., 2013; Scott et al.,
2010). Importantly, defective endocytosis often accompanies
toxicity, and no such ‘‘vacant synapses’’ were observed in
another study (Nemani et al., 2010). It remains possible that
even in the absence of aggregates and overt injury, toxic oligo-
mers account for the inhibition of release by synuclein observed
by multiple groups. However, the ability of the PD-associated
A30P mutation to block the inhibition of release argues against
this possibility. In addition, truncation of the C terminus, which
promotes aggregation of synuclein in vitro and in vivo (Crowther
et al., 1998; Hoyer et al., 2004; Li et al., 2005; Wakamatsu et al.,
2008), had no effect on the inhibition of release, supporting a
specific effect of synuclein independent of toxicity.
Although the phenotype of the single a-synuclein knockout is
relatively modest, the animals show a remarkable resistance
to the parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetra-
hydropyridine (MPTP) (Dauer et al., 2002). Exposure to MPTP
results in the loss of substantia nigra dopamine neurons due to
uptake of the active metabolite N-methyl-4-phenyl-1,2,3,6 -tet-
rahydropyridine (MPP+) by the reuptake transporters for mono-
amines (Javitch et al., 1985), followed by apoptosis triggered
by inhibition of the respiratory chain (Krueger et al., 1990).
The vesicular monoamine transporter (VMAT) protects against
Neuron
ReviewMPP+ toxicity by sequestering the toxin inside secretory vesi-
cles, away from mitochondria, and selection in MPP+ was used
to isolate the cDNA encoding VMAT (Liu et al., 1992a, 1992b).
Subsequent work has confirmed the protection against MPTP
toxicity conferred by loss of a-synuclein (Drolet et al., 2004;
Fornai et al., 2005; Fountaine et al., 2008; Robertson et al.,
2004; Thomas et al., 2011), but strains apparently differ in the
magnitude of this effect (Schlu¨ter et al., 2003). In a-synuclein
knockout mice, mitochondria are not affected by MPTP admin-
istration, suggesting a defect in access, but the activities of
monoamine transporters known to control access of the toxin
appear no different from wild-type (Dauer et al., 2002). Thus,
resistance to MPTP toxicity is one of the more robust aspects
of the a-synuclein knockout phenotype, but the mechanism re-
mains unknown. Although MPTP toxicity differs in important
ways from PD, the ability of the a-synuclein knockout to protect
against the toxin suggests a role for the normal function of syn-
uclein in the pathogenesis of degeneration, particularly since
overexpression of synuclein does not increase vulnerability to
MPTP (Thomas et al., 2011).
The existence of three synuclein isoforms, in many cases ex-
pressed by the same cells, has raised the possibility that redun-
dancy accounts for the modest phenotype of a-synuclein
knockout mice. However, the analysis of a-/b-synuclein double
knockout mice also showed no major change in synapse struc-
ture or excitatory transmission measured electrophysiologically
in hippocampal region CA1 (Chandra et al., 2004). On the other
hand, the a-/b- double knockout does show a modest reduction
in striatal dopamine levels. In addition, a-/g- double and synu-
clein triple knockouts show a substantial increase in striatal
dopamine release in vivo not observed with the single knockouts
(Anwar et al., 2011; Senior et al., 2008). These mutants did not
exhibit a change in dopamine transporter activity or tissue dopa-
mine levels, implicating a specific alteration of dopamine
release. The mechanism remains unknown, but the a-/b- double
knockout shows an increase in complexin (Chandra et al., 2004).
Interestingly, synuclein overexpression reduces complexin
levels (Nemani et al., 2010), suggesting that overexpression
can increase the normal activity of synuclein and that an increase
in the normal function of synuclein contributes to the degenera-
tion produced by its upregulation.
At hippocampal synapses, the effect of the triple knockout has
been controversial. According to one report from the Su¨dhof
laboratory, there was no change in baseline transmitter release
(Burre´ et al., 2010). However, an independent report by a former
member of the same group showed an increase in transmitter
release in the triple knockout (Greten-Harrison et al., 2010).
The increase was small, possibly accounting for the failure to
detect a change by others and raising the possibility that any
change in release might be secondary. Indeed, the loss of all
three synuclein genes results in smaller presynaptic boutons
(Greten-Harrison et al., 2010), suggesting an alternative role for
these proteins.
Previous work has shown a strong genetic interaction
between synuclein and the degeneration produced by loss of
the presynaptic chaperone cysteine string protein (CSPa) (Chan-
dra et al., 2005). Knockout of CSPa does not affect synaptic
transmission shortly after birth but eventually results in rapidlyprogressive synaptic degeneration and death within 2 months
(Ferna´ndez-Chaco´n et al., 2004). CSPa thus does not itself
appear required for transmitter release but rather serves to
maintain the function of the nerve terminal over a longer time
frame. Work from the Su¨dhof laboratory has now suggested
that synuclein may have a similar role in maintenance of the
nerve terminal, rather than transmitter release.
Remarkably, the overexpression of a-synuclein greatly delays
the degeneration due to loss of CSPa, and the loss of synuclein
exacerbates the CSPa knockout phenotype (Chandra et al.,
2005), suggesting that synuclein may have a role as chaperone,
very similar to CSPa. CSPa appears particularly important for the
levels of t-SNARE SNAP-25 (Sharma et al., 2011, 2012). Asmight
be anticipated for a chaperone of the transmitter releasemachin-
ery, the resulting perturbations of SNARE complex assembly are
activity dependent. Since synuclein overexpression inhibits
transmitter release, the resulting decrease in activity might
account for rescue of the CSPa phenotype. However, synuclein
overexpression rescues the reduction in SNARE complex, not
the decrease in SNAP-25 protein levels. The results suggest
that whereas CSPa has a specific role with SNAP-25 that
secondarily affects SNARE complex levels, synuclein has a spe-
cific role in SNARE complex formation and can bypass the
defect in SNAP-25. The original work did not detect biochemical
evidence of a-synuclein associating with the presynaptic SNARE
complex (Chandra et al., 2005), but a subsequent study did
identify a direct biochemical interaction (Burre´ et al., 2010). In
particular, the hydrophilic C terminus of a-synuclein appears to
interact with v-SNARE synaptobrevin 2 (Burre´ et al., 2010).
Consistent with a requirement for the C terminus of a-synuclein
to interact with synaptobrevin, g-synuclein, which diverges in
sequence from a- at the C terminus, does not rescue the loss
of CSPa (Ninkina et al., 2012). In contrast to the role of CSPa
as chaperone for SNAP-25, a-synuclein thus appears to have a
role in SNARE complex formation.
How can a putative chaperone for the SNARE complex either
have no effect on or inhibit transmitter release? The number of
SNARE complexes may not be rate limiting for transmitter
release, and rescue of the degeneration in CSPa knockout
mice does not require an increase in SNAP-25. Regardless of
mechanism, SNARE complex levels correlate more closely
with the degenerative process than with transmitter release.
However, the levels of SNARE complex have not been studied
extensively in animals with other defects in transmitter release
andmay simply reflect changes in another process more directly
affected by synuclein. Indeed, we do not know what comprises
the total pool of SNARE complexes in the brain—cis complexes
on synaptic vesicles or the plasma membrane, trans-complexes
made by docked vesicles or some other pool? Recent work
in vitro has also found that synuclein can inhibit membrane fusion
independent of the SNARE proteins and failed to detect an inter-
action of synuclein with synaptobrevin (DeWitt and Rhoades,
2013). The mechanism by which synuclein rescues the loss of
CSPa thus remains uncertain.
The synuclein triple knockouts do die prematurely but at
around 1 year, a phenotype much milder than the CSP knockout
(Ferna´ndez-Chaco´n et al., 2004; Greten-Harrison et al., 2010).
In addition to smaller presynaptic boutons, the synuclein tripleNeuron 79, September 18, 2013 ª2013 Elsevier Inc. 1049
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obvious synapse loss. The ability to rescue loss of CSPa thus re-
mains perhaps the most dramatic effect of synuclein observed
in vivo, with a very modest degenerative phenotype in synuclein
triple knockout mice alone.
Synuclein has also been reported to interact biochemically
with a large number of proteins that might regulate its activity.
One of the first identified, synphilin appears to promote the
aggregation of synuclein (Engelender et al., 1999; McLean
et al., 2001; Ribeiro et al., 2002). Synphilin also localizes to the
nerve terminal in a synuclein-sensitive manner, but the physio-
logical role of synphilin and its interaction with synuclein remain
unclear. Tubulin appears to interact with a multimeric form of
synuclein, and synuclein can influence the microtubule cytoskel-
eton (Lee et al., 2006). However, the functional ramifications of
this interaction seem more relevant for the toxicity associated
with synuclein than for its normal function (Alim et al., 2002;
Chen et al., 2007; Kim et al., 2008; Lee et al., 2006). Since synu-
clein binds tomembranes in an a-helical conformation, one inter-
esting approach has been to use membrane-bound synuclein as
a probe for conformation-specific interacting proteins (Woods
et al., 2007). This again resulted in the isolation of tubulin but
also other proteins associated with the cytoskeleton. In addition,
this approach identified one novel protein that is natively
unfolded until membrane bound (Boettcher et al., 2008). More
recently, the small GTPase rab3a has been proposed to regulate
the membrane association of a-synuclein in a GTP-dependent
manner (Chen et al., 2013), suggesting functional integration of
synuclein into the cycling of this synaptic vesicle rab and hence
into the synaptic vesicle cycle. However, the role of these poten-
tial regulatory mechanisms remains unclear, largely because we
do not understand the normal function of synuclein.
The Synucleinopathies
Although the normal function of synuclein remains elusive, the
protein has a central role in multiple neurodegenerative pro-
cesses. Indeed, the identification of mutations in a-synuclein
has shifted the focus of work on the pathogenesis of PD from a
specific defect in dopamine neurons to a more widespread
disturbance in the behavior of this protein. Previously, Lewy
bodies had been detected by staining with hematoxylin and
eosin and with somewhat more sensitivity by immunostaining
for ubiquitin. However, immunostaining for a-synuclein revealed
much more widespread deposits in dystrophic neurites as well
as Lewy bodies of cell populations not previously known to be
affected (Galvin et al., 1999; Spillantini et al., 1997, 1998b). In
addition to demonstrating the relevance of synuclein for the idio-
pathic disorder, these observations have suggested a basis for
the nonmotor manifestations of PD (Ahlskog, 2007; Dickson
et al., 2009; Jellinger, 2011). Constipation, hyposmia, depres-
sion, and rapid eye movement (REM) behavior disorder, which
involves the loss of muscle atonia during REM sleep and hence
unsuppressed motor activity while dreaming, can precede the
onset of characteristic parkinsonian motor symptoms by up to
two decades, consistent with the deposition of a-synuclein in
the enteric nervous system, olfactory bulb, dorsal motor nucleus
of the vagus, and glossopharyngeal nerves, as well as other
brainstem nuclei (Postuma et al., 2012). Additional autonomic1050 Neuron 79, September 18, 2013 ª2013 Elsevier Inc.problems (e.g., orthostatic hypotension, incontinence) become
more symptomatic in advanced disease, and synuclein deposits
in autonomic ganglia (Iwanaga et al., 1999; Orimo et al., 2008).
Cortical deposits of synuclein that occur late in the disease
presumably contribute to cognitive problems. Certain nonmotor
manifestations of PD can respond to dopamine replacement,
raising questions about the significance of synuclein deposition
outside the nigrostriatal projection. However, many symptoms
do not respond, and the widespread accumulation of synu-
clein presumably accounts for many of the dopamine-resistant
symptoms.
It is important to note that the relationship between a-synu-
clein deposition and neuronal dysfunction remains unclear. In
the substantia nigra, substantial cell loss occurs before symp-
toms develop, suggesting that protein deposition is not as
important as cell loss. However, cell loss may not accompany
synuclein deposition elsewhere. In the enteric nervous system,
Lewy pathology is indeed not associated with cell loss (Annerino
et al., 2012), raising the possibility of a functional rather than
anatomic disturbance. On the other hand, synuclein deposition
itself may not even produce dysfunction, and pathologic investi-
gation of many older individuals (up to 30% of centenarians) re-
veals extensive synucleinopathy (incidental Lewy body disease)
with no clear neurological symptoms (Ding et al., 2006;Markesb-
ery et al., 2009). Indeed, synuclein aggregation may represent a
neuroprotective response, with a different species of synuclein
responsible for dysfunction. Although synuclein deposition has
thus superseded cell loss as evidence of degeneration, its actual
role in the degenerative process remains unknown.
a-synuclein has also been implicated in at least two other dis-
orders, multiple system atrophy (MSA) and dementia with Lewy
bodies (DLB). Interestingly, these conditions also produce clin-
ical parkinsonism but involve the deposition of a-synuclein in
different cells from those affected by typical PD. MSA can begin
with parkinsonism, autonomic failure, or cerebellar ataxia but
usually progresses to involve one or both of the other compo-
nents, resulting in the recognition that these initially disparate
conditions reflect a common disorder. However, the parkin-
sonism observed in MSA does not generally respond well to
dopamine replacement, presumably because the pathology
affects many cell populations in addition to dopamine-producing
cells of the substantia nigra, including postsynaptic medium
spiny neurons in the striatum (Papp and Lantos, 1994; Sato
et al., 2007). In contrast, PD affects preferentially the dopamine
neurons, with spared postsynaptic cells still responsive to dopa-
mine replacement.
In MSA, a-synuclein deposits in glial (generally oligodendrog-
lial) cytoplasmic inclusions (GCIs) (Spillantini et al., 1998a; Tu
et al., 1998) rather than in the neuronal Lewy bodies or dystro-
phic neurites more characteristic of PD. The expression of
a-synuclein in oligodendrocytes reproduces the MSA pheno-
type, suggesting that the protein there is causative (Shults
et al., 2005; Yazawa et al., 2005). Remarkably, a-synuclein is
not normally expressed by oligodendrocytes (Miller et al.,
2005), and a fundamental question remains about the origin of
this protein: is it taken up from neurons, or does the pathological
process activate expression by glia? In fact, the pathology
shows relatively little deposition of synuclein in neurons, with
Neuron
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2004; Jellinger and Lantos, 2010; Nishie et al., 2004b). At the
same time, oligodendrocytes do not seem to upregulate expres-
sion of a-synuclein even in MSA (Miller et al., 2005). Regardless
of its source, a-synuclein accumulates to particularly high levels
in MSA, suggesting a process distinct from Lewy pathology. In
addition, GCI lesions are widespread inMSA but generally corre-
late with neuron loss in the substantia nigra, pons, cerebellum,
and intermediolateral cell columns of the spinal cord, suggesting
that the glial process may be primary.
MSA is rarely familial (Soma et al., 2006) and mutations in
a-synuclein have not been observed (Ozawa et al., 2006). How-
ever, polymorphisms in the synuclein gene may influence sus-
ceptibility to MSA (Al-Chalabi et al., 2009; Scholz et al., 2009).
In addition, the analysis of familial MSA has recently identified
mutations in COQ2, a protein required for the synthesis of coen-
zyme Q10 (Multiple-System Atrophy Research Collaboration,
2013). The degenerative process in MSA may thus reflect a pri-
mary lesion in mitochondria.
DLB more closely resembles idiopathic PD in terms of Lewy
body pathology. Although DLB appears to be a distinct syn-
drome, with early cognitive impairment, fluctuating alertness,
and visual hallucinations in addition to progressive parkin-
sonism, the distribution of Lewy pathology appears remarkably
similar to that observed in PD, with a brainstem-predominant
form and others involving the cortex as well (McKeith et al.,
2005). Like PD and MSA, DLB also involves primarily the depo-
sition of a-synuclein.
Lewy pathology was originally considered to involve only
a-synuclein, but b- and g- can deposit in both PD and DLB
(Galvin et al., 1999). Similar to a-synuclein, b- accumulates pre-
synaptically in PD, but g- forms axonal spheroids. b-synuclein
has been suggested to ameliorate the toxicity of a-synuclein
by reducing either its aggregation or its expression (Fan et al.,
2006; Hashimoto et al., 2001). However, polymorphisms in
b-synuclein predispose to DLB (Ohtake et al., 2004), and trans-
genic mice overexpressing the variant develop degeneration
and behavioral abnormalities (Fujita et al., 2010). These animals
do not develop typical Lewy pathology, but they do accumulate
both a- and b-synuclein in axonal spheroids (Fujita et al., 2010).
Indeed, b-synuclein appears as toxic as a-synuclein to cultured
neurons (Taschenberger et al., 2013). Mutations in g-synuclein
have not been identified as a cause of familial PD or related
disorders, and it has generally been considered nontoxic, but
recent overexpression of even this isoform has produced degen-
eration in transgenic mice (Ninkina et al., 2009), and a polymor-
phism has also been linked to DLB (Nishioka et al., 2010). Rather
than contribute to disease simply through a decline in their pro-
tective function (Li et al., 2004; Rockenstein et al., 2001), which
nonetheless remains a possibility, b- and g-synuclein may thus
cause degeneration.
a-synuclein also deposits in other neurodegenerative disor-
ders. Alzheimer’s disease shows Lewy pathology in up to 60%
of cases but is more often restricted to the amygdala than in
PD or DLB (Hamilton, 2000; Leverenz et al., 2008; Uchikado
et al., 2006). Neurodegeneration with brain iron accumulation
due to mutations in pantothenate kinase type 2 also exhibit
Lewy pathology labeling for a-synuclein and neuroaxonal spher-oids labeling for b- and g- (Galvin et al., 2000;Wakabayashi et al.,
2000). Thus, synucleins accumulate in a variety of neurodegen-
erative processes, suggesting either that they are sensitive re-
porters for specific cellular defects or that they participate in
the response to injury.
Expression and Clearance
In addition to point mutations, duplication and triplication of the
chromosomal region surrounding the a-synuclein gene have
been found to produce dominantly inherited PD (Ahn et al.,
2008; Singleton et al., 2003). The affected chromosomal region
contains several other genes as well, but the neuropathology re-
veals deposition of synuclein (Seidel et al., 2010; Yamaguchi
et al., 2005), and the phenotypemost likely reflects multiplication
of the a-synuclein gene. In this case, the sequence of synuclein is
wild-type, making the important prediction that a simple in-
crease in the protein rather than a change in its properties suf-
fices to produce PD. The duplication produces a form of PD
similar in onset and symptoms to the sporadic disorder, but
the triplication causes an exceptionally severe phenotype, with
much earlier onset and prominent cognitive as well as motor
impairment (Ahn et al., 2008; Iba´n˜ez et al., 2004; Ross et al.,
2008).
The more global neurologic and behavioral deficits observed
with gene multiplication and point mutation presumably reflect
a generalized increase in synuclein by all of the neurons that nor-
mally express the gene, and a-synuclein is very widely ex-
pressed under normal conditions (Iwai et al., 1995). In contrast,
the preferential involvement in sporadic PD of particular systems
such as the nigrostriatal projection presumably reflects the upre-
gulation of synuclein within specific cells. Indeed, genome-wide
association studies of risk in idiopathic PD reveal the largest con-
tributions from the synuclein gene itself (as well as the microtu-
bule-associated protein tau) (Simo´n-Sa´nchez et al., 2009).
Consistent with a role for the amount of a-synuclein expressed
in the degenerative process, the polymorphisms implicated in
PD lie outside the protein-coding region of the gene and thus
presumably affect mRNA expression. Indeed, one polymor-
phism has been shown to influence expression of a reporter
gene in vitro (Chiba-Falek and Nussbaum, 2001). In addition,
the most common inherited form of PD, due to mutations in
leucine-rich repeat kinase 2 (LRRK2), generally involves Lewy
pathology that may also reflect upregulation of a-synuclein
gene expression (Carballo-Carbajal et al., 2010). Further, a-syn-
uclein has been repeatedly identified as a gene responsive to
toxic insult and growth factors. Injection of the toxin quinolinic
acid directly into the striatum upregulates a-synuclein in the sub-
stantia nigra (Kholodilov et al., 1999), and oxidative stress due to
insecticide or the loss of oxidant defenses also increases a-syn-
uclein (Gillette and Bloomquist, 2003; Gohil et al., 2003). MPTP,
rotenone, and paraquat produce or exacerbate synuclein depo-
sition, and synuclein can protect against some agents (paraquat)
but not others (MPTP) (Fornai et al., 2005; Manning-Bog et al.,
2002, 2003; Przedborski et al., 2001). Synuclein may thus upre-
gulate in response to many forms of injury but help to alleviate
only some and exacerbate others. Perhaps consistent with a
protective role, nerve growth factor induces a-synuclein expres-
sion in PC12 cells and basic fibroblast growth factor in midbrainNeuron 79, September 18, 2013 ª2013 Elsevier Inc. 1051
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Despite these in vitro observations, however, the mechanisms
that regulate synuclein expression in vivo remain poorly
understood, particularly under physiological circumstances.
Interestingly, microRNA-7, which downregulates a-synuclein
expression, itself decreases during MPTP toxicity, providing a
mechanism for the upregulation of synuclein in response to injury
(Junn et al., 2009).
In addition to production, clearance can regulate the levels of
a-synuclein. Like other natively unfolded proteins, synuclein was
originally thought to be degraded by the proteasome without a
requirement for ubiquitination (Bennett et al., 1999; Rideout
and Stefanis, 2002; Tofaris et al., 2001). However, it was subse-
quently found that monoubiquitination apparently promotes the
degradation of synuclein by the proteasome, and this modifica-
tion can be bidirectionally controlled by a specific ubiquitin ligase
(SIAH-2) and deubiquitinase (USP9X) (Liani et al., 2004; Rott
et al., 2011). In addition, considerable evidence has also accu-
mulated to suggest the clearance of synuclein at the lysosome.
Initially thought to promote the clearance of synuclein aggre-
gates by macroautophagy, degradation in the lysosome also
contributes to the turnover of soluble oligomers and even appar-
ently monomeric synuclein under physiological conditions (Lee
et al., 2004; Mak et al., 2010; Rideout et al., 2004). Indeed,
chaperone-mediated autophagy (CMA), a process that targets
individual, soluble proteins to the lysosome for proteolysis, con-
tributes to the clearance of synuclein, and synuclein can in turn
disrupt CMA, altering the turnover of other CMA-dependent pro-
teins (Cuervo et al., 2004; Vogiatzi et al., 2008). Interestingly,
ubiquitination by the ligase Nedd4 has also been shown to target
synuclein for degradation in the lysosome, rather than by the pro-
teasome (Tofaris et al., 2011).
Although we do not know how changes in the expression of
synuclein may actually influence the development of human
PD, recent work has suggested that changes in clearance may
promote degeneration. In particular, idiopathic PD has been
found to associate with mutations in the glucocerebrosidase
(GBA1) gene. Mutations in GBA1 are responsible for Gaucher’s
disease, a recessive lysosomal storage disorder. However, the
spectrum of phenotypes in Gaucher’s disease is very broad,
with type 2 dying within the first 2 years of life and type 1 surviv-
ing longer. Indeed, some of the so-called nonneuropathic type 1
patients eventually develop parkinsonism among other neuro-
logical problems (Alonso-Canovas et al., 2010; Neudorfer
et al., 1996). In addition, it has now become clear that heterozy-
gotes with no overt symptoms of Gaucher’s disease develop PD
at higher rates than controls. GBA1 mutations have been found
in 7% patients with idiopathic PD, and up to 30% of Ashke-
nazi Jewish patients, with only 1.3% in the general population
(Sidransky and Lopez, 2012; Sidransky et al., 2009). Mutations
in GBA1 have also been reported in DLB but not MSA (Farrer
et al., 2009; Segarane et al., 2009), supporting the difference in
mechanism between MSA and Lewy related pathology.
GBA1 mutations presumably increase susceptibility to PD by
blocking the lysosomal degradation of a-synuclein (Manning-
Bog et al., 2009), but it has been difficult to understand how a
modest reduction in enzyme activity could impair lysosomal
function enough to produce a degenerative disorder. Recent1052 Neuron 79, September 18, 2013 ª2013 Elsevier Inc.work has indeed suggested that a-synuclein accumulates in
both a mouse model of Gaucher’s disease and induced pluripo-
tent (iPS) cells from patients with Gaucher’s disease but attrib-
uted the increase to aggregation in the presence of increased
membrane glucocerebroside (Mazzulli et al., 2011). Consistent
with the localization of synuclein to lipid rafts (which are enriched
in sphingolipids such as glucocerebroside) (Fortin et al., 2004),
and its preference for particular lipid acyl chains as well as
head groups (Davidson et al., 1998; Kubo et al., 2005), the mech-
anism by whichGBA1mutations confer susceptibility to PDmay
involve specific effects on cell membranes rather than a more
general disturbance in lysosomal function that simply upregu-
lates the normal protein. Indeed, much of the work on synuclein
has focused on its misfolding and aggregation. Since many
publications have addressed the pathways to misfolding of
a-synuclein, including several recent reviews (Breydo et al.,
2012; Goedert et al., 2013; Lashuel et al., 2013), we will now
summarize the most salient observations.
Misfolding
In contrast to its helical conformation on membranes, synuclein
adopts a b sheet structure in aggregates. Indeed, Lewy bodies
and neurites contain 5–10 nm filaments that appear to be
composed primarily if not exclusively of a-synuclein (Spillantini
et al., 1998b). In brainstem-type Lewy bodies, the pale-staining
halo, which contains filaments by electron microscopy, labels
more strongly for a-synuclein than the acidophilic core (Goedert
et al., 2013). Dystrophic neurites and the less discrete cortical-
type Lewy bodies contain similar filaments (Marui et al., 2002).
Although Lewy bodies were originally considered by some an
artifact of the degenerative process, the identification of a-synu-
clein mutations in familial PD demonstrated a causative role for
the major component of Lewy-related pathology. However, it is
important to remember that this is not the same as establishing
a causative role for Lewy pathology in the degenerative process.
Recombinant synuclein also forms filaments after incubation
in vitro for a protracted period (Conway et al., 1998). By X-ray
diffraction, these filaments adopt a cross-beta structure charac-
teristic of amyloid (Sawaya et al., 2007; Serpell et al., 2000).
Recent solid-state NMR has also begun to analyze fibrils at
high resolution, identifying the repeated units that underlie this
structure (Comellas et al., 2011). Since aggregation has been
considered the critical event in the pathogenesis of PD, the
in vitro assay has received considerable attention. The point
mutations originally identified in familial PD (A53T, A30P, and
E46K) were originally proposed to accelerate aggregation, but
the A30P mutant appears to form fibrils more slowly than the
wild-type, although oligomerization may be enhanced (Conway
et al., 2000; Giasson et al., 1999; Li et al., 2001; Narhi et al.,
1999). b-synuclein does not fibrillize and both b- and g- can
inhibit the aggregation of a-synuclein in vitro and in vivo
(Hashimoto et al., 2001; Uversky et al., 2002), but as noted
above, b- and g- can still contribute to disease (see Synucleino-
pathies above), suggesting that tendency to aggregate may not
correlate closely with potential to cause degeneration.
Many other putative pathogenic factors have also been tested
for their ability to influence the aggregation of synuclein, either
through direct modification of the protein or indirectly through
Neuron
Revieweffects on its environment. a-synuclein does not contain any cys-
teines but can undergo nitration and methionine oxidation in
response to oxidative stress (Breydo et al., 2012; Giasson
et al., 2000a). However, these modifications do not appear to
promote aggregation. Similarly, the a-synuclein that deposits
in Lewy bodies appears more heavily phosphorylated at Ser-
129 than the soluble protein (Fujiwara et al., 2002; Nishie et al.,
2004a). Phosphorylation indeed appears to promote synuclein
aggregation (Smith et al., 2005b), but it remains unclear whether
phosphorylation at this site actually promotes degeneration, with
divergent effects in different models (Azeredo da Silveira et al.,
2009; Chen and Feany, 2005). Deletion of the C terminus pro-
motes both aggregation of synuclein in vitro and pathological
changes in vivo, suggesting an important role for proteolysis in
cells (Li et al., 2005; Murray et al., 2003; Periquet et al., 2007;
Tofaris et al., 2006; Ulusoy et al., 2010). Environmental factors
may also predispose to synuclein aggregation, and heavymetals
appear to promote deposition of the protein in cells as well as
in vitro (Breydo et al., 2012; Paik et al., 1999).
It also remains unclear whether synuclein fibrils promote
toxicity. First, as noted above, the A30Pmutation causes familial
PD but does not promote fibrillization (Conway et al., 2000). Sec-
ond, protein aggregation is not always accompanied by cell loss
in a viral model of PD (Lo Bianco et al., 2002). In a Drosophila
model, aggregates can occur in the absence of toxicity—the
chaperone hsp70 can ameliorate the toxicity of a-synuclein
without affecting inclusions (Auluck et al., 2002). The recently
identified PD-associated a-synuclein mutant G51D also oligo-
merizes more slowly than wild-type a-synuclein but produces a
severe form of degeneration, with early onset and pyramidal as
well as extrapyramidal deficits (Lesage et al., 2013). In addition,
dopamine has been suggested to promote the aggregation of
a-synuclein but not the formation of amyloid (Bisaglia et al.,
2010; Herrera et al., 2008; Rekas et al., 2010). Indeed, dopamine
appears to stabilize synuclein aggregation at the stage of proto-
fibrils, and oligomers of synuclein appear more toxic than fibrils
(Norris et al., 2005; Rochet et al., 2004). There are multiple
cellular mechanisms that regulate the cytosolic concentration
of monoamines, from vesicular monoamine transport to feed-
back inhibition of tyrosine hydroxylase (Fon et al., 1997; Mosh-
arov et al., 2003, 2009), and a change in any of these may thus
increase the interaction with synuclein to produce degeneration.
Taken together, these results suggest that soluble, oligomeric
forms of a-synuclein rather than fibrils may be responsible for
toxicity. However, it is even possible that the monomeric form
contributes. Indeed, gene multiplication causes a substantially
more severe form of PD than the point mutations, and the
amount of synuclein rather than its altered properties may be
the principal factor that increases susceptibility to degeneration.
It is also important to note that althoughmany publications report
the formation of aggregates in transfected cells, often in
response to toxic insult, a-synuclein in fact rarely forms aggre-
gates detectable by immunofluorescence in transfected cells
(R.H.E., unpublished data). The principal form of synuclein in
cells thus appears to be monomer or soluble oligomer.
Although the normal function of synuclein has often been
considered irrelevant for its role in degeneration, the interaction
of synuclein with membranes, which presumably involves ahelical conformation and reflects its normal function, has been
reported to influence misfolding and aggregation. As anticipated
from the structural studies, one report has shown that membrane
association inhibits synuclein oligomerization (Zhu and Fink,
2003), but others have suggested that oligomerization occurs
onmembranes (Jo et al., 2000; Lee et al., 2002a) and can be pro-
moted by polyunsaturated fatty acids (Perrin et al., 2001). It is
important to recognize that the oligomers formed onmembranes
may be helical, as suggested by the recent work using nanopar-
ticles (Varkey et al., 2013); however, recent NMR and EM have
shown directly that anionic phospholipid membranes can
convert helical a-synuclein into fibrils (Comellas et al., 2012). It
will now be important to determine how membranes influence
the conformation and oligomerization of synuclein in cells.
Propagation and Prions
Careful neuropathologic examination of synuclein deposition in
brains with Lewy pathology (from incidental Lewy body disease
to end-stage PD) has suggested that the degenerative process
advances through the nervous system along specific anatomic
pathways (Braak et al., 2003). The first synuclein deposits arise
in either the dorsal motor nucleus of the glossopharyngeal and
vagal nerves or the olfactory bulb (stage 1). In stage 2, the
medulla and pontine tegmentum develop Lewy pathology and
only in stage 3 does synuclein deposition occur in the midbrain
as well as amygdala. At this point, the typical motor manifesta-
tions of PD generally appear. In stage 4, a-synuclein deposits
in temporal cortex, and in stages 5 and 6 in neocortex, presum-
ably contributing to the cognitive deficits observed in LBD and
advanced PD. A minority of cases do not fit this pattern, and iso-
lated Lewy pathology can arise in the amygdala of patients with
AD, but the progression otherwise appears quite stereotyped
(Dickson et al., 2010). The Braak staging of Lewy pathology pre-
sumably accounts for the development of symptoms such as hy-
posmia and REM behavior disorder up to decades before the
onset of typical parkinsonism. It has also suggested a portal of
entry for the disease in either the olfactory mucosa or the gastro-
intestinal tract. Indeed, the retrospective analysis of routine
colon biopsies has recently shown synuclein deposits in the
enteric nervous system years before the clinical onset of PD,
suggesting a useful and accessible biomarker (Shannon et al.,
2012). However, it remains unclear whether the process origi-
nates in the gut, spreading to the CNS through the vagal nerves
rather than the spinal cord, or arises independently at multiple
sites in sympathetic as well as parasympathetic nerves (Bloch
et al., 2006; Iwanaga et al., 1999; Orimo et al., 2008). How then
does misfolded synuclein spread between neurons—directly,
or through effects on the cell that indirectly promote misfolding?
Several observations have suggested that misfolded synu-
clein may propagate through a prion-like mechanism (Lee
et al., 2010b; Olanow and Prusiner, 2009). First, fetal dopamine
cells transplanted into the striatum of patients with PD were
found to develop Lewy pathology when examined neuropatho-
logically one to two decades later (Kordower et al., 2008; Li
et al., 2008). The clear implication is that the normal synuclein ex-
pressed by these cells begins to misfold and aggregate after
exposure to the abundant misfolded a-synuclein of the host.
This has indicated limits to the therapeutic potential of graftsNeuron 79, September 18, 2013 ª2013 Elsevier Inc. 1053
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folded protein to act as a template for conversion of the normal
species to an abnormal conformation. Like the form of a-synu-
clein associated with membranes, the normal cellular form of
the prion protein PrP(c) indeed appears predominantly helical,
whereas the pathogenic form Prp(Sc), like the a-synuclein in
Lewy pathology, is mostly b sheet (Colby and Prusiner, 2011).
In the absence of spread between organisms, PD clearly differs
from typical prion disorders such as Jakob-Creutzfeldt disease,
scrapie, and bovine spongiform encephalopathy but may use a
similar mechanism to amplify the pathogenic species at the level
of the protein, without a need for nucleic acid (Prusiner, 2001).
Second, the apparent inability of oligodendrocytes to make
a-synuclein under either normal or pathologic circumstances
(Miller et al., 2005; Spillantini et al., 1998a; Tu et al., 1998) re-
quires a mechanism for transfer from the site of production, pre-
sumably in neurons, to the GCIs of MSA.
It was not initially clear how a cytosolic protein like synuclein
might spread between cells—PrP is a lipid-anchored protein fac-
ing the cell exterior. However, it was recognized even before
recent interest in the prion hypothesis for PD that small amounts
of a-synuclein can undergo secretion through a vesicular mech-
anism (Lee et al., 2005). More recently, it has become apparent
that synuclein release can involve exosomes, the luminal mem-
branes of multivesicular bodies (mvbs) normally targeted for
degradation by the lysosome (Emmanouilidou et al., 2010).
This is particularly plausible because mvbs form through the
invagination of endosomal membranes and would thus be ex-
pected to trap cytosolic proteins such as synuclein. Of course,
this would also imply the regulated release of other cytosolic pro-
teins, and the full extent of this mechanism for release remains
unclear. It is also possible that oligomeric forms of synuclein,
perhaps enriched on the pathway to degradation by the lyso-
some, become particularly susceptible to release. In addition,
this release appears capable of calcium-dependent regulation
(Lee et al., 2005; Paillusson et al., 2013), providing an activity-
dependent mechanism for propagation that may be relevant
for spread along synaptically connected pathways. However, it
remains unclear how much of the synuclein released occurs
through exosomes as opposed to other, less well-characterized
pathways.
Several reports have also documented the uptake of fibrillar
synuclein by cells and its ability to produce aggregates
composed primarily of the endogenous, host cell protein.
Initially, propagation involved either cell extracts including
proteins other than a-synuclein or required transduction of
preformed recombinant fibrils into cells overexpressing synu-
clein (Desplats et al., 2009; Luk et al., 2009). It was shown
subsequently, however, that fibrils of recombinant synuclein
can enter neurons directly by endocytosis and seed the forma-
tion of aggregates resembling Lewy pathology in cells that
express only endogenous levels of synuclein (Volpicelli-Daley
et al., 2011). The mechanism of uptake remains poorly under-
stood, but glia can also take up synuclein derived from neu-
rons, suggesting a mechanism for the formation of GCIs in
MSA (Lee et al., 2010a), although it remains unclear how the
process could propagate in the absence of any endogenous
glial a-synuclein.1054 Neuron 79, September 18, 2013 ª2013 Elsevier Inc.Synuclein also appears capable of spread between cells
in vivo. Similar to the human transplants described above, cells
transplanted into a transgenic animal model can acquire mis-
folded synuclein from the adjacent tissue and form aggregates
(Desplats et al., 2009). Direct injection of fibrillar recombinant
synuclein into transgenic mice overexpressing the PD-associ-
ated A53T mutant also promotes aggregate formation and
disease, with knockouts protected against any pathologic
changes (Luk et al., 2012b). However, these transgenic animals
would develop degeneration even without injection. More
recently, it has been possible to inject fibrils of recombinant
mouse a-synuclein into the striatum of wild-type mice, resulting
in synuclein aggregates in the substantia nigra, dopamine cell
loss, and parkinsonian deficits (Luk et al., 2012a), and this
model of propagation has come the closest yet to demon-
strating propagation of the misfolded protein under relatively
normal circumstances in vivo. Nonetheless, it still involves injec-
tion of extremely large amounts of fibrillar synuclein, and the
involvement of dopamine neurons requires only uptake of the
fibrils in the striatum, not actually propagation between neu-
rons. Deposits were described in other brain regions such as
the cortex and thalamus (Luk et al., 2012a), but at least some
of these also project directly to the dorsal striatum and do
not require spread between neurons. Regardless, a prion-like
mechanism of transmission suggests that improved clearance
of synuclein with circulating antibodies has considerable thera-
peutic potential (Bae et al., 2012).
Although the data are thus far consistent with a prion-like
mechanism for the transmission of misfolded synuclein
between cells, there are several important differences between
PD and known prion disorders. First, although the incubation
time can be long, most prion disorders result in a subacute
clinical decline over weeks to months, and PD progresses
over decades, particularly since certain features can long pre-
cede the onset of typical parkinsonian symptoms. Second, it
is important to note that although Lewy pathology was recog-
nized in a few cells of some human transplants, many of the
grafts and indeed most of the transplanted cells even in
affected grafts appeared entirely normal (Mendez et al., 2008).
The process thus does not seem very efficient. Third, the mis-
folded state in typical prion disorders is quite stable and,
indeed, heritable—different strains of the same misfolded pro-
tein reproducibly produce distinct forms of degeneration. How-
ever, very recent work has suggested that the conformation of
misfolded synuclein can change over time and indeed promote
the aggregation of an entirely distinct protein (tau) (Figure 3)
(Guo et al., 2013). Considering the importance of tau for
neurodegenerative disease as a whole and PD in particular
(Simo´n-Sa´nchez et al., 2009), this work expands the relevance
of synuclein aggregation but suggests important differences
from typical prion disorders.
Fourth and perhaps most important, sporadic prion disorders
presumably involve a very rare misfolding event, which then
propagates through the prion mechanism. Consistent with this,
overexpression of wild-type PrP does not by itself usually suffice
to produce prion disease. In the case of human PD, however,
overexpression of wild-type a-synuclein due to gene triplication
produces more severe disease than the point mutations, even
Figure 3. Synuclein Exhibits Prion Strain-like Properties
Fibrils of recombinant synuclein were taken up by primary neurons and the
derived fibrils used for repetitive seeding of additional primary cultures. Early
passages yield fibrils capable of forming only inclusions of synuclein (strain A).
Fibrils derived from subsequent passages produced robust tau pathology with
less deposition of synuclein (strain B). Both strains may derive from the same
initial fibrillization reaction (gray arrows), but it seems more likely that strain A
converts into strain B. (Adapted from Guo et al., 2013.)
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to aggregate. For PD, the amount of protein expressed thus
appears particularly important, suggesting differences from the
prion disorders. PD may simply reflect an increase in mono-
meric, rather thanmisfolded or oligomeric, synuclein. In addition,
the particular sensitivity to expression may reflect the enhance-
ment of a less rare misfolding event by increased protein. Alter-
natively, wild-type synuclein may misfold at such a high rate that
its concentration is more important than any small difference in
aggregation tendency. Interestingly, the recent overexpression
of wild-type bank vole PrP in mice has been found to produce
degeneration and prions, but only one variant does this and
bank vole PrP appears unusually susceptible to prion formation
(Watts et al., 2012). Rather than a rare misfolding event that re-
quires propagation to cause disease, the misfolding of a-synu-
clein (and possibly bank vole PrP) might therefore originate at
multiple sites, with fewer requirements for transmission between
cells.Toxicity: Membranes
How does synuclein cause toxicity? The analysis of synuclein in
multiple systems has suggested a role for its interaction with
membranes. As noted above, synuclein oligomers can permea-
bilize membranes in vitro (Rochet et al., 2004; Tsigelny et al.,
2007; Volles et al., 2001), but the relevance of this observation
for cells has remained unclear. To study its toxicity in vivo, over-
expression of human a-synuclein in yeast has provided an
experimentally tractable system (Outeiro and Lindquist, 2003).
Although yeast do not contain any sequences resembling synu-
clein, overexpression of the human protein appears to interfere
with transport through the early secretory pathway, and genes
that modify the toxicity of synuclein in yeast also tend to involve
lipid metabolism and membrane trafficking (Willingham et al.,
2003). The small GTPase rab1 that operates early in the secre-
tory pathway rescues synuclein toxicity, both in yeast and in
mammalian cells overexpressing a PD-associated mutant
(Cooper et al., 2006; Gitler et al., 2008). This might be considered
a nonspecific effect, but additional work has suggested an inter-
action of synuclein with rabs (Chen et al., 2013; Dalfo´ et al., 2004;
Lee et al., 2011; Rendo´n et al., 2013). In the absence of a
clear rab-related defect in synuclein knockout mice, the physio-
logical significance remains unclear, but it may have a role in
degeneration.
In yeast, overexpressed a-synuclein localizes to punctate
structures. EM has shown that these accumulations are in fact
clusters of vesicles rather than proteinaceous deposits, and
synuclein appears to act by inhibiting membrane fusion (Gitler
et al., 2008; Soper et al., 2008), similar to what has been reported
in chromaffin cells (Larsen et al., 2006) (see Role in Neurotrans-
mitter Release above). Human synuclein can also produce lipid
droplets in yeast (Outeiro and Lindquist, 2003). Regardless of
mechanism, a mutational analysis of synuclein has also shown
that toxicity in yeast correlates with the strength of membrane in-
teractions rather than the tendency to aggregate (Volles and
Lansbury, 2007). However, the behavior of synuclein in mamma-
lian cells differs in many respects from that observed in yeast,
with less obvious membrane association and toxicity, particu-
larly with the wild-type protein. In addition, human synuclein
cannot form lipid droplets in mammalian cells but does coat
and stabilize the fat droplets formed by feeding with oleic acid
(Cole et al., 2002). Perhaps most dramatically, the g-synuclein
knockout shows resistance to obesity and increased lipolysis
in white adipose tissue, apparently through increased access
of lipolytic enzymes to fat droplets (Millership et al., 2012). The
effect of this knockout on brain phospholipids is modest
(Guschina et al., 2011), but the effect on adipose tissue strongly
supports a role for the other isoforms as well in membrane
access and modification.
In recent years, structural studies in vitro have suggested that
when synuclein binds to membranes, it can remodel them
(Bodner et al., 2009; Diao et al., 2013). The analysis of mitochon-
drial morphology has now corroborated this possibility in cells.
Implicated in the pathogenesis of Parkinson’s disease by the
MPTP model and the role in mitochondrial autophagy of
recessive PD genes parkin and PINK1 (Narendra et al., 2012),
mitochondria have been found to interact with synuclein in
several ways. In addition to protection against MPTP toxicityNeuron 79, September 18, 2013 ª2013 Elsevier Inc. 1055
Figure 4. a-Synuclein Tubulates Membranes In Vitro
(A) Recombinant a-synuclein (600 mM) clarifies an opaque solution containing
phosphatidylglycerol with palmitoyl and oleoyl side chains (60 mM) (Varkey
et al., 2010). (Republished with permission from the Journal of Biological
Chemistry.)
(B) Twenty mM recombinant a-synuclein was added to nonextruded, 0.4 mm
membranes containing a 1:1 mixture of dioleoyl phosphatidyl choline and
dioleoyl phosphatidic acid (400 mM) and examined by negative staining
electron microscopy (T.P.L. and R.H.E., unpublished data). Size bar indi-
cates 100 nm.
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Reviewby inactivation of the a-synuclein gene (Dauer et al., 2002; Fornai
et al., 2005; Fountaine et al., 2008; Klivenyi et al., 2006), both
overexpression and loss of synuclein have been reported to
impair mitochondrial function (Ellis et al., 2005; Martin et al.,
2006; Smith et al., 2005a; Stichel et al., 2007). Synuclein also
binds to mitochondria (Cole et al., 2008; Devi et al., 2008; Li
et al., 2007; Liu et al., 2009; Nakamura et al., 2008). More
recently, however, overexpression of a-synuclein in a variety of
cell types including neurons has been found to fragment mito-
chondria (Kamp et al. 2010; Nakamura et al., 2011). The change
in mitochondrial morphology appears specific, with minimal
morphological change in other organelles (such as the Golgi
complex), and precedes any deterioration in mitochondrial
function (Nakamura et al., 2011).
How does synuclein overexpression fragment mitochondria?
Using a direct assay, synuclein does not prevent mitochondrial
fusion but rather promotes fission and acts independently of
the major fission protein Drp1 (Nakamura et al., 2011). The frag-
mentation also requires access of synuclein to mitochondria,
suggesting a direct effect of synuclein on mitochondrial mem-
branes. Indeed, recombinant synuclein can fragment artificial
membranes containing the mitochondrial lipid cardiolipin but
not membranes without an acidic phospholipid headgroup
(Nakamura et al., 2011). Consistent with sequence conservation
of the N-terminal membrane-binding domain, b- and g-synuclein
can also affect mitochondrial morphology (Nakamura et al.,
2011).
The Langen group has independently provided compelling
evidence that synuclein can remodel membranes (Jao et al.,
2008; Varkey et al., 2010). Dramatically, high concentrations of
recombinant synuclein can turn an opaque solution of artificial
membranes clear (Figure 4A). At intermediate concentrations,
synuclein produces massive tubulation, very similar to Bin-
amphysin-Rvs (BAR) domain proteins that bend membranes
(McMahon andBoucrot, 2011;MimandUnger, 2012) (Figure 4B).
However, synuclein seems to act through a distinct mechanism
that may involve electrostatic interaction with the phospholipid
headgroups to bind membranes but requires insertion into the
bilayer for membrane bending (Jensen et al., 2011). In particular,
synuclein appears to insert in an extended helical conformation
parallel to the long axis of the tubule (Mizuno et al., 2012). The
preference of synuclein for highly curved membranes and
the ability to tubulate membranes may indeed derive from the
same ability to recognize defects in the lipid bilayer (Ouberai
et al., 2013; Pranke et al., 2011), similar to the amphipathic lipid
packing sensor motifs desribed in ArfGAP1 (Antonny, 2011).
Synuclein can also cluster artificial membranes and, consistent
with previous work, the A30Pmutation disrupts membrane tubu-
lation (Diao et al., 2013; Nakamura et al., 2011; Zigoneanu et al.,
2012).
The analysis of knockout mice further supports a role for
synuclein in membrane bending. A proteomic analysis of the
triple knockouts shows reciprocal changes in BAR domain
proteins, in particular endophilin (Westphal and Chandra,
2013). This work also demonstrates the effect of synuclein on
membrane curvature in vitro. In contrast to another study
suggesting that a multimeric form of synuclein was responsible
for tubulation (Nakamura et al., 2011), this report indicated a1056 Neuron 79, September 18, 2013 ª2013 Elsevier Inc.requirement for the monomeric protein (Westphal and Chandra,
2013).
Despite these observations, synuclein normally resides at
presynaptic boutons, and most mitochondria localize to the
cell body and dendrites. How then can synuclein influence mito-
chondrial behavior in neurons? We hypothesize that synuclein
localizes to mitochondria only when upregulated. The high pre-
synaptic concentration of synaptic vesicles with high curvature
presumably accounts for the normal localization of synuclein to
this site. If expression is increased, however, synuclein may
then also associate with other membranes such as the mito-
chondrial innermembrane, which has high curvature at particular
sites and is exceptionally rich in the acidic phospholipid cardio-
lipin. Indeed, the level of expression correlates with mitochon-
drial fragmentation (Nakamura et al., 2011).
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Recent work now indicates the potential for propagation of mis-
folded synuclein between cells, through a prion-like mechanism.
However, the events that trigger misfolding of synuclein in the
first place remain poorly understood. A simple increase in the
amount of a-synuclein appears sufficient, but its interaction
with membranes probably has a crucial role. Lower levels of syn-
uclein contribute to its physiological role at the nerve terminal,
influencing the amount of SNARE complex either directly, as a
chaperone, or indirectly through other effects on the synaptic
vesicle cycle. When upregulated through physiological or patho-
logical mechanisms, synuclein may target other membranes
such as mitochondria, and this presumably accounts for the
toxicity observed in human PD. The interaction with membranes
thus appears central to both the normal function of synuclein and
its role in degeneration. Determining how this interaction influ-
ences the conformation of synuclein will help to understand
the misfolding that occurs in PD. Similarly, understanding how
the interaction affects membrane behavior will illuminate the
normal function of the protein, provide a biological context to un-
derstand its regulation, and indicatemechanisms responsible for
toxicity. However, all of these questions await better methods to
understand the behavior and activity of synuclein within the cell.
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